---
document_datetime: 2026-01-20 12:33:49
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: elfabrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3097781
conversion_datetime: 2026-01-20 20:28:45.728712
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Elfabrio

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 20/01/2026                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000319765           | Update of the package leaflet with revised contact details of local representatives and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.   |                                                                                                                                                                                                                                                               |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000248528 | - -                                                                                                                                                                                                                   | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit balance of medicinal products containing pegunigalsidase alfa remains unchanged and therefore recommends the maintenance of the marketing authorisation(s). |